Celsion Corporation (Nasdaq: CLSN) announced that following a review of data from its multinational, randomized pivotal Phase III clinical study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE